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Abstract
Aims/hypothesis In this study, we used an immunodeficient
mouse model to explore, in vivo, the longitudinal adaptation
of human islets to an obesogenic environment.
Methods Non-diabetic Rag2–/– mice (n061) were trans-
planted with human islets (400 islet equivalents [IEQ]) from
six pancreases: four non-diabetic and two with overt metabol-
ic dysfunction (older, high HbAlc or history of diabetes).
Animals were fed for 12 weeks with a control or high-fat diet
(HFD), and followed for weight, serum triacylglycerol, fasting
blood glucose and human C-peptide. After the mice were
killed, human grafts and the endogenous pancreas were ana-
lysed for endocrine volume, distribution of beta and alpha
cells, and proliferation.
Results Transplanted mice on an HFD gained significantly
more weight (p<0.001) and had higher fasting glycaemia
(2–12 weeks; p00.0002) and consistently higher fasting
human C-peptide levels (2–12 weeks; p00.04) compared
with those on the control diet. Histology demonstrated dou-
bling of human islet graft volume at 12 weeks in animals on
the HFD and increased beta cell volume (p<0.001), but no
change in alpha cell volume. Human islet function (hyper-
bolic product HOMA2%BS) at 12 weeks was four times
lower in HFD animals (p<0.001 vs controls) because of
insufficient beta cell adaptation to decreased (70%) sensi-
tivity (HOMA%S). Human islets obtained from donors with
metabolic dysfunction failed to adapt to the HFD.
Conclusions/interpretation This longitudinal study provides
direct evidence that human islets adapt both endocrine and
beta cell mass, function and gene expression to obesity in
vivo. The present model will facilitate the identification of
mechanisms by which human islets adapt to obesity in vivo
and the cell type(s) responsible, and factors predisposing
human beta cells to decompensation.
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Decoding how diabetes and obesity are interrelated is a com-
plex and interdisciplinary research endeavour [1, 2]. Islet
adaptation to obesity is well established in rodents, where
islets compensate for insulin-resistant states by increasing beta
cell mass and function tomaintain normoglycaemia [3].Major
differences have, however, emerged in the field of beta cell
biology between rodent and human cells, making work with
human islets crucial [4]. Indeed, clinically, most obese indi-
viduals do not develop diabetes because islets compensate for
insulin resistance [5, 6]. Yet direct evidence that human islet
mass adapts longitudinally to obesity in vivo is lacking and,
moreover, little information is available on the mechanisms
and cell type(s) involved. Current evidence for increased beta
cell mass in obese humans (vs lean) is based entirely on
postmortem histology [7]. Beta cell mass quantification in
humans by in vivo imaging is nascent [8] and should
one day enable longitudinal studies.
The aim of this study was to explore the longitudinal adap-
tation of human islets to an obesogenic environment. The
transplantation of human islets into immune-compromised
mice is a validated technique with which to study human beta
cells in an in vivo environment [9] and when human C-peptide
levels are measured, this technique provides a quantitative
assessment of human islet function [10, 11]. In this study, we
transplanted human islets into an immunodeficient mouse
strain sensitive to high-fat diet (HFD)-induced obesity and
show direct evidence that non-diabetic human islets adapt
both endocrine and beta cell mass, function and gene ex-
pression to obesity in vivo. However, dysfunctional human
islets showed arrested adaptation. This model may foster
deciphering of the mechanisms by which human islets
adapt to obesity and the cell type(s) that are responsible,
and possibly identify key factors predisposing human beta
cells to decompensation [1].
Methods
Human islets Pancreases were harvested from human brain-
deceased donors in agreement with French regulations and
with our institutional ethics committee, and were processed
for islet isolation as previously described [12]. Four of the
pancreases were from non-diabetic donors and two were
from donors with overt metabolic dysfunction (older, high
HbAlc or a history of diabetes; see electronic supplementary
material [ESM] Tables 1 and 2). All islets showed more than
90% viability after culture, but were quantitatively insuffi-
cient for clinical islet transplantation [13].
Animals, human islet transplantation and induction of
obesity Male C57BL6 Rag2–/– immunodeficient mice of
8–9 weeks old (n061; courtesy of A. Bouloumié, Inserm
U858, Toulouse, France [14], and RAGN12-M, Taconic,
Germantown, NY, USA) were transplanted under the kidney
capsule as previously described [10] with 400 human islet
equivalents (IEQ). Mouse studies were performed in accor-
dance with the guidelines from the local animal experimen-
tation committee. As previously described, islets from each
human donor were distributed symmetrically across exper-
imental groups to control for potential differences in islet
quality between the donors [15]. Eight to ten mice were
transplanted per donor per condition. Animals were fed for
12 weeks with a control diet or HFD (NJ ref D12450B;
Research Diets, New Brunswick, NJ, USA; ESM Table 3).
All mice were followed for 12 weeks for weight, serum
triacylglycerol, 6 h fasting blood glucose and human
C-peptide. At the end of the study, mice were fasted for
6 h before receiving an oral bolus of glucose (2 g/kg body
weight) diluted in saline buffer (0.9% sodium chloride). Tail
blood was collected at 0, 30 and 60 min after administration
to evaluate human C-peptide levels (ultrasensitive human
C-peptide kit; Mercodia, Uppsala, Sweden). Blood glucose
was measured up to 180 min (Accu-Chek Go glucometer;
Roche, Meylan, France). HOMA, calculated using fasting
human C-peptide and blood glucose levels in mice
(www.dtu.ox.ac.uk/homacalculator/index.php) [16], was
used as an index of insulin sensitivity (HOMA2%S), beta
cell function (HOMA2%B) and the hyperbolic product
(HOMA2%S×HOMA2%B/100). Results of 12 clinical-
grade islet preparations (glycaemia, human C-peptide) trans-
planted into 20 immunodeficient mice, as previously de-
scribed [10], were used to calculate theoretical HOMA2%B
andHOMA2%S. Fat content was quantified byMRI using ten
images/mouse before killing, as previously described [17].
Immunohistochemistry To assess proliferation, BrdU was
injected 18 h before the mice were killed or administered
for 7 days in the drinking water. Both the endogenous
mouse pancreas and human grafts were fixed and embedded
in paraffin for sectioning and analysis of endocrine mass,
distribution of beta cells and proliferation. Endocrine mass
of the endogenous pancreas was determined with Papanico-
laou staining of sections [18]. For endocrine mass assess-
ment in human islet grafts, the entire block was sectioned;
one section every 50 μm was immunolabelled with chromog-
ranin A primary antibody (M0869, 1/100; Dako, Glostrup,
Denmark) and revealed with Envision (K4003; Dako).
Similarly, beta and alpha cell volumes were determined using
Alexa 488-conjugated anti-humanC-peptide (green) (Monsam,
Uden, the Netherlands) or anti-glucagon (G2654; Sigma, Saint-
Quentin-Fallavier, France) using the Lightning-Link Conjuga-
tion Kit (Innova Biosciences, Cambridge, UK); nuclei were
stained with DAPI (blue) (H-1200J; Vector Laboratories,
Burlingame, CA, USA).
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Endocrine or beta cell proliferation in grafts was respective-
ly determined with three-colour fluorescence staining, BrdU–
Chromogranin A–DAPI or BrdU–insulin–DAPI, or Ki67-
replaced BrdU (MIB-1; M7240, 1/100; Dako). After antigen
retrieval (microwave, citrate buffer pH6), tissues were incu-
bated overnight at 4°C with primary rat anti-BrdU antibody
(AbD, BU1/75, 1/100; Serotec, Paris, France) followed by
goat anti-rat Alexa Fluor 594 antibody (A11007, 1/300; Invi-
trogen, St Aubin, France). Double labelling was performed
with rabbit anti-chromogranin A (M0869, 1/100; Dako) or
mouse anti-insulin/proinsulin (AbD; D6C4, 1/300; Serotec),
followed by donkey anti-rabbit Alexa Fluor 488 antibody
(A21206, 1/300; Invitrogen) or goat anti-mouse Alexa Fluor
488 (A11001, 1/300; Invitrogen). Double labelling for chro-
mogranin A, the pan-endocrine marker, and cytokeratin 19, as
described [19, 20] suggestive of endocrine neogenesis, was
quantified as previously described (the number of CK19-
positive ductal cells co-stained with chromogranin A) [7].
Morphometric analysis To quantify the total islet surface of
human graft sections and islet surface in mouse pancreases,
slides were scanned with a Nikon Eclipse Ti microscope, and
the fractional area was digitally quantified (Nis Elements AR
3.0) (Nikon, Champigny sur Marne, France). Planimetry, used
for clinical tumour volume appreciation (surface in mic-
rons2×distance in microns between paraffin sections), was
used to determine endocrine, beta and alpha volumes (μm3
or mm3) of entire human islet grafts. Leica DM-R microscope
and ImageJ (National Institutes of Health, Bethesda, MD,
USA) were used for the quantitative analysis.
RNA tissue extraction and Q-PCR RNA was isolated from
snap-frozen human islet grafts (n014) immediately after
killing using the RNeasy Micro Kit (Qiagen, Paris, France).
RNA quantification was performed with the NanoDrop
spectrophotometer (ND-1000; Thermo Scientific, Wilming-
ton, NC, USA) and reverse transcription of 0.5 μg/μl RNA
was performed with the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Paris, France). For
small human samples, pre-amplification of the gene of in-
terest was performed with the TaqMan PreAmp Kit (Ap-
plied Biosystems), followed by quantitative PCR analysis
(SYBR Green; Applied Biosystems). The INS primers (for-
ward: 5′GCAACTAGACGCAGCCCGCA′3; reverse:
5′GGCTTTATTCCATCTCTCTCGGTGC′3) were designed
on the basis of sequence alignments of the INS region of
human species and unrelated to the mouse; β-actin was the
reference gene. Only one amplification product for INS (86°C)
and for actin (82°C) was observed in human islets grafts and
none for genomic DNA from the mouse kidney.
Statistical analysis For each variable, the change over time
(2 and 12 weeks; denoted 2–12 weeks) as well as the
difference at any given time was compared according to
the two groups (control vs HFD) using analysis of variance
based on a linear mixed model in order to adjust for the
donor effect. The fixed effect was the group and the random
effect was the donor. The same procedure was used to
compare the histological data at 12 weeks according to the
two groups. The analysis of repeated measurements for
weight was also performed using the linear mixed model.
In this analysis, the effect ‘donor’ was considered as a
random effect and the correlations between the repeated
measurements were modelled by using a first autoregressive
covariance model. Our choice of this model was based on
Akaike’s information criterion. The validity of the linear
mixed model was checked using the analysis of the resid-
uals; the normality of residuals was tested with the Shapiro–
Wilk test and the outliers were identified using box plots.
The influence of each individual on the results was investi-
gated using the Cook distance. If necessary, the stability of
results after removing outliers or influential individuals was
checked. Data were plotted as mean±SEM.
Statistical analyses were performed using StatView (SAS
Institute, Cary, NC, USA) and SAS (SAS Institute Inc., Cary,
NC, USA). p values<0.05 were considered statistically
significant.
Results
HFD-induced obesity in Rag2–/– mice transplanted with
human islets A preliminary study using young (4-week-
old) or adult male immunodeficient C57BL6 Rag2–/– mice
(n014) confirmed that adults, as suggested [14, 21], gain
weight on an HFD similar to male C57BL6 wild-type ani-
mals after 12 weeks (p00.110, results not shown). All
subsequent experiments used adult male Rag2–/– mice with
a human islet graft.
Even with a human islet graft, Rag2–/– mice on a HFD
gained considerable weight (Fig. 1a) as compared with mice
on the control diet (p<0.0001). This corresponded to higher
BMI, serum triacylglycerol levels (Fig. 1b) and fat indices
(ESM Table 4), including abdominal fat measured with MRI
(Fig. 1c: HFD 52.27±4.39% vs controls 25.7±0.604%, p<
0.05) in adult Rag2–/– HFD mice vs controls.
Confirmation of adaptation of endogenous pancreas Mor-
phometric analysis of the endogenous mouse pancreas con-
firmed that total islet area was doubled in HFD mice. There
was no difference in the number of islets (per mm2 tissue
surface) between the two groups (ESM Table 4), but the
islets were larger and the proportion of beta cells higher in
the pancreases of mice on the HFD at 12 weeks. Total
pancreatic and endocrine cell proliferation was elevated in
the endogenous pancreases of HFD mice.
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Histological assessment at 12 weeks of the human grafts in
animals on control or HFD Morphometric analysis with
chromogranin A (Fig. 2a, 196–210 sections/group; see
Methods) confirmed the more than doubling of human en-
docrine graft volume (HFD 0.094±0.017 vs controls 0.042
±0.008 mm3; p00.0006) (Fig. 2b). To determine if this was
due to endocrine cell hypertrophy of human islets as pro-
posed [22] in HFD animals, individual cell surfaces were
measured; no difference was observed (HFD 138±5.9 μm2
vs controls 135.3±4.6 μm2; p00.7). Indeed a 2.6-fold in-
crease in beta cell volume (Fig. 2c; HFD 0.071±
0.0021 mm3 vs controls 0.027±0.001 mm3; p00.0006) was
observed at 12 weeks (Fig. 2d), yet alpha cell volume was
identical between the groups (Fig. 2e; HFD 0.011±0.002mm3
vs controls 0.009±0.002 mm3; p00.0735). It is worth noting
that human beta cells represented 64±2.0% and 75±1.86% of
the total endocrine volume at 12 weeks in control and HFD
mice, respectively (p<0.05), whereas alpha cells made up a
18.08±1.49% in control animals and a statistically significant-
ly smaller proportion in HFD animals (12.45±1.69%, p<
0.05). Relative expression of human INS mRNAwas 3.4-fold
higher in human islets grafted in HFD mice (Fig. 3).
Total proliferation in human grafts, assessed at 12 weeks
in all donors after overnight incubation with BrdU, was four
times greater in HFD animals (BrdU-positive nuclei/total
nuclei in graft: HFD 1.027±0.259% vs controls 0.259±
0.157%; p00.03). When BrdU was administered 1 day prior
to mouse killing at 12 weeks, endocrine islet cell prolifera-
tion (double chromogranin A/BrdU cells) (Fig. 4a) was low
in all animals at 12 weeks (Fig. 4b), as was beta cell
proliferation (double insulin/BrdU-positive cells; 1/1,500
cells; p0NS). Anti-human anti-Ki67 antibody (Fig. 4c)
showed that general proliferation in human grafts was
higher in HFD mice (HFD 0.467±0.082% vs controls
0.214±0.054%, p00.03) and endocrine cell proliferation
(double chromogranin A/Ki67) was higher, albeit insignifi-
cantly in HFD animals (HFD 0.254±0.065% vs controls
0.119±0.034%; p00.08) (Fig. 4d). Beta cell proliferation
Fig. 1 (a) Weight gain (% of baseline) over 12 weeks in animals
grafted with human islets from four donors. White squares, HFD grafts
(n023); black squares, controls (n022) (linear mixed model, see
Methods, ***p<0.001). (b) Serum triacylglycerol levels at 12 weeks
(*p<0.05 vs controls). (c) MRI was used to quantify (10 sections/
mouse) abdominal fat content (expressed as a percentage±SEM) be-
fore the mice were killed (HFD 52.27±4.39% vs controls 25.7±
0.604%, *p<0.05, fat appears in white) Fig. 2 (a) Representative sections of paraffin-embedded human grafts
stained with the endocrine marker chromogranin A (DAB, brown) in
HFD and control-diet mice (scale bar, 50 μm). (b) Morphometric
analysis for total endocrine volume (chromogranin A) (HFD [n06]
vs control [n07], >196 sections/group; linear mixed model, see Methods,
***p<0.001). (c) Sections of paraffin-embedded human grafts stained
with the beta cell marker C-peptide (green). (d) Morphometric analysis
for beta cell volume (HFD [n06] vs control [n07], ***p<0.001). (e)
Morphometric analysis for alpha cell volume (HFD [n06] vs control
[n07])
Fig. 3 Expression of the human INS gene in grafts (HFD [n07] vs
control [n07]; *p<0.05) (see Methods)
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(double Ki67/insulin-positive) at 12 weeks showed no statis-
tically significant difference between groups (HFD 0.067±
0.033% vs 0.058±0.028%; p00.1) (Fig. 4e).
We subsequently performed a kinetic study in mice trans-
planted with human islets, where BrdU was administered in
the drinking water for 7 days prior to killing at 4, 6, 8 or
12 weeks (ESM Fig. 1a). Cumulative 7 day chromogranin
A-positive endocrine proliferation (not shown) appeared
higher at 12 weeks in HFD animals vs controls in accor-
dance with the 1 day BrdU labelling, but also at 6 weeks
HFD (results not shown). We also readily detected (4%)
7 day cumulative proliferation in C-peptide-positive human
beta cells at 6 and 12 weeks. Double labelling for ductal
(anti-cytokeratin 19) and a pan-endocrine marker (anti-chro-
mogranin A) was maximum at 8 weeks HFD (vs controls),
suggesting the potential contribution of endocrine neogenesis
(ESM Fig. 1b). Although further confirmation is required,
both proliferation and neogenesis appear to potentially con-
tribute to the expanded human islet mass in animals on an
HFD.
Assessment of human islet graft function Fasting glycaemia
was higher in HFD mice compared with controls at
2–12 weeks (p00.0002) (Fig. 5a). It should be noted that
the fasting glycaemia of Rag2–/– mice (n011) with no islet
graft was 6.83±0.28 mmol/l. Compared with controls, HFD
animals had a tendency towards higher plasma human
C-peptide levels after 12 weeks compared with 2 weeks
(2 weeks: controls 172.42±28.75 pmol/l vs HFD 479.54±
Fig. 4 (a) Proliferation was
determined on sections of
human grafts at 12 weeks
following an overnight
incubation with BrdU
(nuclei in blue, BrdU in red,
chromogranin A [chromoA]
in green or merge). (b) BrdU/
chromogranin A endocrine-
positive cell quantification in
human islet grafts (HFD [n04]
vs control [n05]). (c) Prolifera-
tion with Ki67 in beta cells
(image shows merge of insulin
in red, Ki67 in green). Quanti-
fication of (d) Ki67/chromog-
ranin A and (e) Ki67/insulin-
positive cells in human islets
grafts (HFD [n04] vs control
[n05]; linear mixed model,
see Methods, p00.08)
Fig. 5 (a) Fasting glycaemia (mmol/l) in animals with a human graft
subsequently placed on an HFD (white bars) or control (black bars)
diet (2–12 weeks, linear mixed model, see Methods, ***p<0.001). (b)
Human C-peptide in tail blood plasma over the 12 week period in HFD
(white bars; n020) vs control diet (black bars; n019) animals
(2–12 weeks, linear mixed model, see Methods, *p<0.05). (c) Evolu-
tion of HOMA2%B and HOMA2%S in animals at 2 weeks (circles) or
12 weeks (squares) on an HFD (white) or control diet (black) (mean±
SEM), plotted on hyperbolic curve (see Methods; the dotted lines
represent the upper and lower 95% CIs of the mean). (d) Hyperbolic
product (HOMA2%BS) in mice implanted for 12 weeks with non-
diabetic human islets (HFD) [white bars] vs controls [black bars] at
12 weeks (***p<0.001; *p<0.05 controls, 2 vs 12 weeks)
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148.84 pmol/l; 12 weeks: controls 370.89±97.91 pmol/l vs
HFD 1,081.41±216.32; 2–12 weeks, p00.04) (Fig. 5b).
Results for individual human islet donors are depicted in
ESM Fig. 2. Human C-peptide expressed as a function of
glycaemia was also higher at 12 weeks (vs controls).
We used a surrogate HOMA2 based on fasting glycaemia
and human C-peptide levels to longitudinally determine
changes in human islet graft function in animals at 2 and
12 weeks. Figure 5c shows HOMA2%B and HOMA2%S
for animals with respect to hyperbolic product value
(HOMA2%B×HOMA2%S/100), calculated as described in
the Methods (the dotted lines represent the upper and lower
95% confidence intervals of the mean). No difference was
observed at 2 weeks between the two groups. An increase in
HOMA2%B was observed with time in both control and
HFD animals (respectively, 2–12 weeks, p00.0075 and p0
0.06). Control animals showed no change in HOMA2%S
over time (p00.412); however, HFD animals showed a
deterioration in HOMA2%S (>70% at 12 week vs 2 weeks,
p00.03) corresponding to a 1.7-fold increase in insulin resis-
tance (HOMA-IR01/HOMA-S×100) over time and com-
pared with control animals at 12 weeks. Increased peripheral
insulin resistance was also confirmed in insulin tolerance tests
(not shown). As a result, human islet function (hyperbolic
product HOMA2%BS) showed an improvement over time
(2–12 weeks, p00.02) in control animals that was not ob-
served in HFD animals at 12 weeks (Fig. 5d); HOMA2%BS at
12 weeks was four times lower in HFD animals (vs controls,
p<0.001) due to insufficient beta cell adaptation to decreased
(70%) sensitivity (HOMA%S). An OGTT (n018 mice) at
12 weeks (Fig. 6a) showed slightly abnormal glucose toler-
ance in HFD animals (vs AUCglucose in control group, p0
0.001); basal human C-peptide secretion and 60 min post
glucose stimulation were higher in islets transplanted in
HFD animals (vs controls, p00.06; Fig. 6b), but only control
islets were stimulated by glucose.
To further test the model, we evaluated the adaptation of
islets isolated from two donors with overt disturbances in
glucose metabolism (older donors, high HbAlc or a history
of diabetes; ESM Table 2). As described in the Methods,
islets from each donor were distributed symmetrically
across the experimental groups. Despite identical weight
gain, higher blood glucose levels were observed earlier in
HFD animals grafted with diabetic islets. No functional adap-
tation to HFD was observed (HOMA-B and C-peptide/gly-
caemia levels were lower in the HFD group vs controls),
which was confirmed by low HOMA2%BS values at
12 weeks. Morphometric analysis showed no adaptation of
endocrine volume to the HFD compared with control non-
diabetic donors, and beta cells only accounted for approxi-
mately 10% of diabetic islets (% C-peptide surface/chro-
mogranin A surface) compared with 64±2.0% (control) to
75±1.86% (HFD) in non-diabetic donor islets (ESM Fig. 3).
No proliferation could be detected.
Discussion
In this study, we have explored the longitudinal adaptation
of human islets to an obesogenic environment and showed
direct evidence that non-diabetic human islets adapt both
endocrine and beta cell mass, function and gene expression
to obesity in vivo. In fact, Tyrberg et al were the first to
show the proof of concept that human islets xenotransplanted
into obese hyperglycaemic–hyperinsulinaemic ob/ob mice
could adapt to murine obesity [23] but the mice required
immunosuppression, which attenuates islet compensation
[24], limiting graft follow-up to 2 weeks. After first testing
C57BL6male nu/numice that do not gainweight on a 12week
HFD (results not shown), adult male Rag2–/– animals (lym-
phocyte B and T deficient) were selected after a pilot study, to
address the question: can human islets adapt to an obesogenic
environment in mice? In this particular study, we first pur-
posely chose young donors since they are most likely to adapt.
Second, we chose not to render the animals diabetic and to use
a mini-human islet graft—400 IEQ vs the 2,000 IEQ classi-
cally used to cure diabetes, since this enables one to follow the
adaptation to obesity in both the endogenous murine islets as
well as the human cells. In fact, a mini-graft of <500 islets was
chosen since higher numbers of islets (1,000, 2,000 and
3,000 IEQ) lead to an atrophy of endogenous islets (J. Kerr-
Conte, unpublished observation) in accordance with previous
publications [25, 26].
Concomitant with the increased weight gain, doubling of
abdominal fat, increased serum triacylglycerol and reduced
insulin sensitivity (HOMA-S) in 12 week HFD animals (vs
controls), we report that human islet grafts (400 islets)
showed functional compensation, measured as a more than
doubling of fasting human C-peptide in mouse serum (vs
controls), and histological adaptation of islet endocrine mass
including increased beta cells. Increased human islet
C-peptide secretion may be the simple result of islet
Fig. 6 (a) Representative blood glucose levels during an OGTT
12 weeks after human islet transplantation, HFD (white squares, n0
9) vs control diet (black squares, n09) (5–120 min, *p<0.05). (b)
Human C-peptide secretion at 0 and 60 min in islets transplanted in
HFD animals (white bars) compared with controls (black bars) (HFD
vs controls at 0 min, *p<0.05, and at 60 min, p00.06)
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adaptation to hyperglycaemia [27] yet, in this study, in-
creased blood glucose levels were only observed at
12 weeks; it should be noted that glycaemia in HFD animals
was lower than in C57BL6 wild-type or Rag2–/– animals on
an HFD (results not shown). This has been previously
attributed to the human set point (1.0 g/l) of trans-
planted cells compared with the mouse set point (1.5–
2.0 g/l), as previously described for human embryonic stem-
cell-derived islets grafted into non-diabetic immunodeficient
mice [11]. In addition, increased C-peptide/glycaemia was
also observed over time in mouse fed an HFD (vs controls at
12 weeks).
The doubling of human endocrine islet volume and in-
creased percentage of beta cells (%beta/endocrine cells)
paralleled the adaptation of the murine endogenous pancre-
as. At 12 weeks, total proliferation was higher in both the
endogenous pancreas and the human graft in HFD animals.
Human endocrine islet cell proliferation at 12 weeks, deter-
mined with Ki67, was higher in HFD grafts (vs controls,
albeit p00.08) but beta cell proliferation was extremely rare.
In initial studies, BrdU was administered the day before
killing and not for 4 [27] to 7 days or 1 month, as recently
published [28], which might be responsible for the extremely
low beta cell proliferation seen in our study. Ki67/chromog-
ranin A-positive cells exhibited twofold greater proliferation
than BrdU/chromogranin A-positive cells, but beta cell pro-
liferation remained rare to absent.
In a subsequent kinetic study (ESM Fig. 1), BrdU was
administered for 7 days in the drinking water prior to killing.
Cumulative 7 day endocrine proliferation and C-peptide
beta cell proliferation had a tendency to be higher at 6 and
12 weeks in HFD animals vs controls. Chromogranin
A-positive ductal cells, suggestive of neogenesis, peaked
at 8 weeks in HFD grafts. It should be noted that we
purposely double-labelled with the pan-endocrine marker
chromogranin A and cytokeratin 19, and not insulin/cyto-
keratin 19, in order to identify all neoformed endocrine cells
as previously described [19, 20]. Further kinetic studies are
required, yet it would appear that both proliferation and
neogenesis can potentially contribute to the expanded islet
mass. Future kinetic studies will combine permanent tag-
ging of human beta cells (or alpha cells) prior to trans-
plantation, as previously described [29], to bring
definitive proof of the cell origin responsible for the
doubling of the endocrine mass.
In this study, we used the fasting state HOMA of beta cell
function (HOMA2) in the mouse as a surrogate to follow
modifications in islet function in vivo. Identical at 2 weeks,
marked increases were observed in HOMA2%B in both
control and HFD animals with time. Only HFD led to a
marked decrease in insulin sensitivity (HOMA-S). Classically,
a reduction in insulin action in non-diabetic individuals is
accompanied by compensatory increases in beta cell secretion
(HOMA2%B) [30], where HOMA2%BS thus remains
unaltered. If islets are defective, reduced HOMA2%BS
values are observed. In this study the hyperbolic product
(HOMA2%BS), which was identical in the two groups at
2 weeks post-transplantation, improved significantly in con-
trol animals over time (2 vs 12 weeks), suggesting a hyper-
functional state of the animals that had both a small ectopic
human graft (400 IEQ) and a persisting endogenous
pancreas. HOMA2%BS did not increase in HFD ani-
mals between 2 and 12 weeks, and was four times
lower than HOMA2%BS in control animals at 12 weeks.
This suggests that although human islets adjust to in-
creased insulin resistance by increasing human C-peptide
secretion, normal human islets in an obese environment
are defective. This was confirmed by OGTT results, which
were also abnormal at 6 and 12 weeks in HFD animals (vs
controls).
One limitation of our study is the use of HOMA in our
combined human–murine model. Exploitation of this clini-
cal tool in the rodent has been described [31] but remains
controversial [16, 32]. Use of HOMA in this study is inter-
esting and specific (human C-peptide), but may be the
subject of debate since fasting glycaemia in this model can
be regulated by both the human graft and the endogenous
pancreas still in place, which also adapts as evidenced by a
doubling of the murine islet mass on an HFD. Nevertheless,
in our study this variable mainly allowed us to compare the
different groups, all of which had a human islet graft from
the same donors and endogenous pancreas.
To further validate the model, we had the opportunity to
study the adaptation capacity of human islets from two
dysfunctional human donors. Despite similar weight gain,
animals had higher fasting glycaemia and showed no func-
tional (human C-peptide) or histological adaptation of en-
docrine graft volume at 12 weeks. The hyperbolic plot, as
well as HOMA2%BS, illustrates the lack of adaptation.
Human islet grafts from dysfunctional donors were made
up of only 10–20% beta cells compared with 75% in normal
human islets. Part of the incapacity of dysfunctional islets to
adapt may be linked to the age of the donors (>60 years), as
has been suggested [28, 33], although other authors have
incriminated BMI [27].
In conclusion, we exploited an immunodeficient mouse
strain to determine the influence of an obesogenic environ-
ment on human islets, and show for the first time direct
evidence that non-diabetic human islets adapt both endo-
crine and beta cell mass, function and gene expression to
murine obesity in vivo. This novel model allows, for the
first time, longitudinal studies of human islet adaptation to
an obese murine environment and may be instrumental in
deciphering pathways involved in human beta cell expan-
sion, as well as in helping to identify factors predisposing
human beta cells to undergo decompensation [1]. In
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addition, the concomitant presence of a mini-human islet
graft and the endogenous murine pancreas, both of which
doubled in islet/endocrine surface, will allow scientists to
study in parallel alterations in murine and human cell ex-
pansion at the same time in response to obesity. This will be
key to identifying major differences between human and
murine pancreatic cells.
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